Literature DB >> 6282040

Aminoglycoside-induced cochlear pathology in man.

L G Johnsson, J E Hawkins, T C Kingsley, F O Black, G J Matz.   

Abstract

Temporal bones from five patients with hearing loss as a result of aminoglycoside treatment were examined by the method of microdissection and surface preparations, followed by celloidin embedding and serial sectioning of the modiolus. Three patients had received the newer antibiotics, gentamicin, tobramycin, and amikacin; the other two neomycin. In the cochleas from two patients of the first group there was only a small loss of hair cells, restricted to the lower end of the basal turn. The third, who had been treated with several antibiotics over a longer period of time, showed more extensive but strikingly asymmetrical patterns of degeneration in the two ears. This patient, as well as the fourth, who had received neomycin during peritoneal lavage, had numerous patchy areas of complete disappearance of Corti's organ in the basal turn, with incipient degeneration of the distal ends of the nerve fibers in adjacent portions of the osseous spiral lamina. The fifth patient, who had become deaf after prolonged treatment with neomycin by mouth, showed a complete loss of cochlear hair cells. Nerve fibers were present only in the middle and upper turns, where supporting cells remained. Midmodiolar sections showed a proportionately much greater loss of the distal than of the proximal processes of the cells of the spiral ganglion. These findings underscore once again the special hazard for the inner ear that is associated with the clinical use of neomycin, regardless of the route of administration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6282040

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  24 in total

Review 1.  Aminoglycoside-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

2.  Spatial selectivity to intracochlear electrical stimulation in the inferior colliculus is degraded after long-term deafness in cats.

Authors:  Maike Vollmer; Ralph E Beitel; Russell L Snyder; Patricia A Leake
Journal:  J Neurophysiol       Date:  2007-09-12       Impact factor: 2.714

3.  Across-site patterns of modulation detection: relation to speech recognition.

Authors:  Soha N Garadat; Teresa A Zwolan; Bryan E Pfingst
Journal:  J Acoust Soc Am       Date:  2012-05       Impact factor: 1.840

4.  Psychophysically based site selection coupled with dichotic stimulation improves speech recognition in noise with bilateral cochlear implants.

Authors:  Ning Zhou; Bryan E Pfingst
Journal:  J Acoust Soc Am       Date:  2012-08       Impact factor: 1.840

5.  Generation of inner ear hair cells by direct lineage conversion of primary somatic cells.

Authors:  Louise Menendez; Talon Trecek; Suhasni Gopalakrishnan; Litao Tao; Alexander L Markowitz; Haoze V Yu; Xizi Wang; Juan Llamas; Chichou Huang; James Lee; Radha Kalluri; Justin Ichida; Neil Segil
Journal:  Elife       Date:  2020-06-30       Impact factor: 8.140

Review 6.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

7.  Characteristics of detection thresholds and maximum comfortable loudness levels as a function of pulse rate in human cochlear implant users.

Authors:  Ning Zhou; Li Xu; Bryan E Pfingst
Journal:  Hear Res       Date:  2012-01-04       Impact factor: 3.208

8.  Cochlear ototoxicity of chlorhexidine gluconate in cats.

Authors:  Y Igarashi; J Suzuki
Journal:  Arch Otorhinolaryngol       Date:  1985

9.  Mucosal injuries following intratympanic applications of chlorhexidine gluconate in the cat.

Authors:  Y Igarashi; Y Oka
Journal:  Arch Otorhinolaryngol       Date:  1988

Review 10.  Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.

Authors:  Jochen Schacht; Andra E Talaska; Leonard P Rybak
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.